HAE is caused by a defect in the gene that controls a protein known as C1 inhibitor. C1 inhibitor helps regulate certain complex reactions in the body, including reactions that lead to the production of bradykinin. Bradykinin is a chemical that causes blood vessels to dilate (widen) and leak fluid into surrounding tissue. It is this leakage of fluid that is thought to cause the swelling and painful attacks associated with HAE.
In people with HAE, the body either does not produce enough C1 inhibitor or produces C1 inhibitor that does not function properly. As a result, too much bradykinin is produced, blood vessels leak fluid, and swelling and painful attacks can occur.
Cinryze works by replacing C1 inhibitor that is missing or not working properly in people with HAE, thereby preventing attacks from occurring.
Cinryze is approved for use in adolescents (generally defined as children who are at least 13 years old). It has not been adequately studied in younger children or infants. Talk to your child's healthcare provider about the risks and benefits of using this medication in children.
Yes, older adults can use this medicine. However, there were not enough older adults in clinical trials to determine if they respond to or tolerate Cinryze any differently than younger individuals. Therefore, older adults may need to be monitored more closely until more information is available about using this drug in older adults.
On occasion, your healthcare provider may recommend this medication for treating something other than the condition discussed in this article. This is called an "off-label" use. Prescribing Cinryze to treat HAE attacks that are already occurring would be an example of an off-label use.